PT  - JOURNAL ARTICLE
AU  - Lawrence Sher
AU  - Giovanni Passalacqua
AU  - Camille Taillé
AU  - Lauren Cohn
AU  - Santiago Quirce
AU  - Nadia Daizadeh
AU  - Nami Pandit-Abid
AU  - Benjamin Ortiz
AU  - Asif H. Khan
AU  - Yi Zhang
TI  - Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma
AID  - 10.1183/13993003.congress-2021.PA3733
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3733
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3733.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3733.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Background: The Asthma Quality of Life Questionnaire (AQLQ) includes items assessing the impact of asthma on sleep in patients (pts). Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VENTURE (NCT02528214), DPL 300mg every 2 weeks (q2w) vs placebo (PBO) reduced oral corticosteroid (OCS) maintenance dose and rate of severe asthma exacerbations and improved pre-bronchodilator FEV1 and health-related quality of life in pts with OCS-dependent, severe asthma. DPL was generally well tolerated.Aim: To assess the effect of DPL on pt-reported sleep outcomes in VENTURE.Methods: Four AQLQ items assess the impact of asthma on sleep on a scale of 1–7; scores of 6/7 indicate little/no impact of asthma. The proportion of pts with scores of 6/7 on the sleep-related items (#5, #20, #24, and #29) was evaluated at baseline (BL), Week (Wk) 12 and 24.Results: The proportion of pts reporting little/no impact of asthma on sleep-related items at BL was 17%–37%, suggesting that most pts experienced sleep impairment. A greater proportion of DPL pts vs PBO reported little/no impact of asthma on sleep at Wk 24 (P<0.01 for item #20) (Figure).Conclusion: Pts with OCS-dependent, severe asthma had impaired sleep at BL. At Wk 24, a greater proportion of DPL pts reported waking up with asthma symptoms hardly any or none of the time vs PBO. FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3733.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).